Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agios Pharmaceuticals Inc AGIO

Healthcare Biotechnology
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined... see more

Recent & Breaking News (NDAQ:AGIO)

Agios Reports Business Highlights and Third Quarter 2022 Financial Results

GlobeNewswire November 3, 2022

Agios and Sagard Healthcare Partners Announce $131.8 Million Purchase Agreement for TIBSOVO® Royalty

GlobeNewswire October 27, 2022

Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022

GlobeNewswire October 20, 2022

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer

GlobeNewswire September 26, 2022

Agios Appoints Cecilia Jones as Chief Financial Officer

GlobeNewswire September 19, 2022

Agios Receives Positive CHMP Opinion for PYRUKYND® (mitapivat) for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

GlobeNewswire September 16, 2022

Agios to Participate in September Investor Conferences

GlobeNewswire August 24, 2022

Agios Announces Publication of Phase 3 ACTIVATE-T Data in The Lancet Haematology Demonstrating Benefits of PYRUKYND® (mitapivat) for Adults with Pyruvate Kinase Deficiency

GlobeNewswire August 18, 2022

Agios Appoints Rahul Ballal and Cynthia Smith to Board of Directors

GlobeNewswire August 15, 2022

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

GlobeNewswire August 11, 2022

ProKidney Strengthens Board of Directors with Appointments of Dr. John M. Maraganore and Jennifer Fox

GlobeNewswire August 11, 2022

Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Executive Officer

GlobeNewswire August 8, 2022

Agios Reports Business Highlights and Second Quarter 2022 Financial Results

GlobeNewswire August 4, 2022

Agios to Webcast Conference Call of Second Quarter 2022 Financial Results on August 4, 2022

GlobeNewswire July 14, 2022

Agios Appoints Brian Goff as Chief Executive Officer

GlobeNewswire July 12, 2022

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

GlobeNewswire June 13, 2022

Agios Presents New Clinical Data Supporting the Benefits of PYRUKYND® (mitapivat) Treatment in Adults with PK Deficiency at European Hematology Association Annual Congress

GlobeNewswire June 10, 2022

Agios Announces Evolution of Research Organization

GlobeNewswire May 16, 2022

Agios to Present Clinical and Translational Data at the European Hematology Association Annual Congress

GlobeNewswire May 12, 2022

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 17, 2022

GlobeNewswire May 10, 2022